Intracerebral haemorrhage during alemtuzumab administration

Lancet Neurol. 2019 Apr;18(4):329-331. doi: 10.1016/S1474-4422(19)30076-6. Epub 2019 Feb 15.

Authors

Christina J Azevedo¹, Christen Kutz², Amy Dix³, Aaron Boster⁴, Nerses Sanossian⁵, Jeffrey Kaplan³

Affiliations

¹ Department of Neurology, University of Southern California, Los Angeles, CA 90033, USA. Electronic address: cazevedo@usc.edu.
² Colorado Springs Neurological Associates, Colorado Springs, CO, USA.
³ College Park Family Care Center, Overland Park, KS, USA.
⁴ OhioHealth Neurological Physicians, Columbus, OH, USA.
⁵ Department of Neurology, University of Southern California, Los Angeles, CA 90033, USA.

PMID: 30777657
DOI: 10.1016/S1474-4422(19)30076-6

No abstract available

Publication types

Letter

MeSH terms

Adult
Alemtuzumab / adverse effects*
Alemtuzumab / therapeutic use
Blood Pressure / drug effects
Cerebral Hemorrhage / chemically induced*
Cerebral Hemorrhage / drug therapy
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / complications
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Retrospective Studies
Risk Factors

Substances

Alemtuzumab